


This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1. – 4. (Canceled)

5. (Previously presented) A compound of formula (I)



wherein:

R¹ is a [2-(cyclopropylcarbonylamino)phenyl]carbonylmethyl or [2-(pyridylcarbonylamino)phenyl]carbonylmethyl group;

R² is a methyl group;

R³ is a 2-buten-1-yl, 3-methyl-2-buten-1-yl, or a 2-butyne-1-yl group; and

R⁴ is a (3-aminopiperidin-1-yl) group,

or a prodrug or salt thereof.

6. (Previously presented) A compound selected from:

(1) 1-(2-[2-[(cyclopropylcarbonyl)amino]phenyl]-2-oxoethyl)-3-methyl-7-(3-methyl-2-

buten-1-yl)-8-(3-aminopiperidin-1-yl)xanthine;

(2) 1-(2-{2-[(cyclopropylcarbonyl)amino]phenyl}-2-oxoethyl)-3-methyl-7-((E)-2-buten-1-yl)-8-((R)-3-aminopiperidin-1-yl)xanthine;

(3) 1-(2-{2-[(cyclopropylcarbonyl)amino]phenyl}-2-oxoethyl)-3-methyl-7-((E)-2-buten-1-yl)-8-((S)-3-aminopiperidin-1-yl)xanthine;

(4) 1-(2-{2-[(cyclopropylcarbonyl)amino]phenyl}-2-oxoethyl)-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-aminopiperidin-1-yl)xanthine;

(5) 1-(2-{2-[(cyclopropylcarbonyl)amino]phenyl}-2-oxoethyl)-3-methyl-7-(2-butyn-1-yl)-8-((S)-3-aminopiperidin-1-yl)xanthine; and

(6) 1-[2-(2-{[(pyridin-2-yl)carbonyl]amino}phenyl)-2-oxoethyl]-3-methyl-7-((E)-2-buten-1-yl)-8-(3-aminopiperidin-1-yl)xanthine,

or a prodrug or salt thereof.

7. – 10. (Canceled)

11. (Original) The compound of formula (I) according to claim 5, wherein the compound is a physiologically acceptable salt.

12. (Previously presented) The compound according to claim 6, wherein the compound is a physiologically acceptable salt.

13. (Previously presented) A pharmaceutical composition comprising a compound of

formula (I) according to claim 5 and an inert carrier or diluent.

14. (Previously presented) The pharmaceutical composition according to claim 13, wherein the compound of formula (I) is incorporated with the inert carrier or diluent by mixing.

15. (Canceled)

16. (Currently Amended) A method of treating ~~type I and~~ type II diabetes mellitus, ~~or obesity,~~ comprising administering to a patient in need thereof a pharmaceutically effective amount of a compound according to claim 5 or 6.

17. (Previously presented) A method of treating or preventing type II diabetes mellitus or obesity, comprising administering to a patient in need thereof a pharmaceutically effective amount of a compound according to claim 5 or 6.

18. (Previously presented) A pharmaceutical composition comprising a compound according to claim 6 and an inert carrier or diluent.

19. (Previously presented) The pharmaceutical composition according to claim 18, wherein the compound is incorporated with the inert carrier or diluent by mixing.